Phase I trial of exisulind (sulindac sulfone, FGN-1) as a chemopreventive agent in patients with familial adenomatous polyposis

Clinical Cancer Research

Volumn 6, Issue 1, 2000, Pages 78-89

  Van Stolk, Rosalind ^a,b   Stoner, Gary ^c   Hayton, William L ^c   Chan, Kenneth ^c   DeYoung, Barry ^c   Kresty, Laura ^c   Kemmenoe, Brian H ^c   Elson, Paul ^b   Rybicki, Lisa ^b   Church, James ^a,b   Provencher, Kim ^b   McLain, Denise ^a   Hawk, Ernest ^d   Fryer, Ben ^e   Kelloff, Gary ^d   Ganapathi, Ram ^a   Thomas Budd, G ^a,b  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SULINDAC SULFONE; UNCLASSIFIED DRUG;

ADENOMATOUS POLYP; ADULT; ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER DYSFUNCTION; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ADENOMATOUS POLYPOSIS COLI; ADMINISTRATION, ORAL; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; APOPTOSIS; FEMALE; HALF-LIFE; HUMANS; IN SITU NICK-END LABELING; KI-67 ANTIGEN; MALE; MIDDLE AGED; SULINDAC;

EID: 0033956565     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parker, S., Tong, T., Bolden, S., and Wingo, P. Cancer Statistics. CA J. Clin., 47: 5-27, 1997.
2. Steele, G. J. Accomplishment and promise in the understanding and treatment of colorectal cancer. Lancet, 342: 1092-1096, 1993.
3. Nishisho, I., Nakamura, Y., Miyoshi, Y., Miki, Y., Ando, H., Horii, A., Koyama, K., Utsunomiya, J., Baba, S., and Hedge, P. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science (Washington DC), 253: 665-669, 1991.
4. Powell, S. M., Petersen, G. M., Krush, A. J., Booker, S., Jen, J., Giardiello, F. M., Hamilton, S. R., Vogelstein, B., and Kinzler, K. W. Molecular diagnosis of familial adenomatous polyposis [see comments]. N. Engl. J. Med., 329: 1982-1987, 1993.
5. Thun, M. J., Namboodiri, M. M., and Heath, C. W., Jr. Aspirin use and reduced risk of fatal colon cancer [see comments]. N. Engl. J. Med., 325: 1593-1596, 1991.
6. Peleg, II, Maibach, H. T., Brown, S. H., and Wilcox, C. M. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer [see comments]. Arch. Intern. Med., 154: 394-399, 1994.
7. Rosenberg, L., Palmer, J. R., Zauber, A. G., Warshauer, M. E., Stolley, P. D., and Shapiro, S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer [see comments]. J. Natl. Cancer Inst., 83: 355-358, 1991.
8. Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., and Offerhaus, G. J. Treatment of colonie and rectal adenomas with sulindac in familial adenomatous polyposis. N. Engl. J. Med., 328: 1313-1316, 1993.
9. Subbaramaiah, K., Zakim, D., Weksler, B. B., and Dannenberg, A. J. Inhibition of cyclooxygenase: a novel approach to cancer prevention. Proc. Soc. Exp. Biol. Med., 216: 201-210, 1997.
10. Boolbol, S. K., Dannenberg, A. J., Chadburn, A., Martucci, C., Guo, X. J., Ramonetti, J. T., Abreu-Goris, M., Newmark, H. L., Lipkin, M. L., DeCosse, J. J., and Bertagnolli, M. M. Cyclooxygenase-2 overexpression and tumor formation are blocked by sulindac in a murine model of familial adenomatous polyposis. Cancer Res., 56: 2556-2560, 1996.
11. Chiu, C. H., McEntee, M. F., and Whelan, J. Sulindac causes rapid regression of preexisting tumors in min/+ mice independent of prostaglandin biosynthesis. Cancer Res., 57: 4267-4273, 1997.
12. Thompson, H. J., Briggs, S., Paranka, N. S., Piazza, G. A., Brendel, K., Gross, P. H., Sperl, G. J., Pamukcu, R., and Ahnen, D. J. Inhibition of mammary carcinogenesis in rats by sulfone metabolite of sulindac. J. Natl. Cancer Inst., 87: 1259-1260, 1995.
13. Piazza, G. A., Rahm, A. K., Finn, T. S., Fryer, B. H., Li, H., Stoumen, A. L., Pamukcu, R., and Ahnen, D. J. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res., 57: 2452-2459, 1997.
14. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
15. Ray, G. F., Lanman, R. C., Fu, C. J., Paranka, N. S., Pamukcu, R., and Wheeler, S. C. Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. J. Pharm. Biomed. Anal., 14: 213-220, 1995.
16. Piazza, G. A., Alberts, D. S., Hixson, L. J., Paranka, N. S., Li, H., Finn, T., Bogert, C., Guillen, J. M., Brendel, K., Gross, P. H., Sperl, G., Ritchie, J., Burt, R. W., Ellsworth, L., Ahnen, D. J., and Pamukcu, R. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res., 57: 2909-2915, 1997.
17. Ray, G. F., Lanman, R. C., Fu, C. J., Paranka, N. S., Pamukcu, R., and Wheeler, S. C. Determination of FGN-1 (an active metabolite of sulindac) in human plasma, urine, and feces by HPLC. J. Pharm. Biomed. Anal., 14: 213-220, 1995.
18. WinNonlin Standard Edition, Version 1.1. Lexington, Kentucky: Scientific Consulting, Inc.
19. Excel, Version 5.0. Microsoft, Inc.
20. SYSTAT for Windows, Version 5. Evanston, Illinois: SYSTAT, Inc.
21. LogXact, Version 1.01. Cambridge, Massachusetts: Cytel Software Corporation, 1992.
22. Gavrieli, Y., Sherman, Y., and Ben-Sasson, S. A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119: 493-501, 1992.
23. Kawamura, K. I., Grabowski, D., Weizer, K., Bukowski, R., and Ganapathi, R. Modulation of vinblastine cytotoxicity by dilantin (phenytoin) or the protein phosphatase inhibitor okadaic acid involves the potentiation of anti-mitotic effects and induction of apoptosis in human tumour cells. Br. J. Cancer, 73: 183-188, 1996.
24. Aoyama, M., Grabowski, D. R., Isaacs, R. J., Krivacic, K. A., Rybicki, L. A., Bukowski, R. M., Ganapathi, M. K., Hickson, I. D., and Ganapathi, R. Altered expression and activity of topoisomerases during all-trans retinoic acid-induced differentiation of HL-60 cells. Blood, 92: 2863-2870, 1998.
25. Oshima, M., Oshima, H., Kitagawa, K., Kobayashi, M., Itakura, C., and Taketo, M. Loss of APC heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncated APC gene. Proc. Natl. Acad. Sci. USA. 92: 4482-4486, 1995.
26. Oshima, M., Dinchuk, J. E., Kargman, S. L., Oshima, H., Hancock, B., Kwong, E., Trzaskos, J. M., Evans, J. F., and Taketo, M. M. Suppression of intestinal polyposis in APC Δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 87: 803-809, 1996.
27. Elder, D. J., Halton, D. E., Hague, A., and Paraskeva, C. Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin. Cancer Res., 3: 1679-1683, 1997.
28. Piazza, G. A., Rahm, A. L., Krutzsch, M., Sperl, G., Paranka, N. S., Gross, P. H., Brendel, K., Burt, R. W., Alberts, D. S., Pamukcu, R., et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res., 55: 3110-3116, 1995.
29. Thompson, H. J., Jiang, C., Lu, J., Mehta, R. G., Piazza, G. A., Paranka, N. S., Pamukcu, R., and Ahnen, D. J. Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res., 57: 267-271, 1997.
30. Schnitzler, M., Dwight, T., and Robinson, B. G. Sulindac increases the expression of APC mRNA in malignant colonie epithelial cells: an in vitro study. Gut, 38: 707-713, 1996.
31. Mahmoud, N. N., Boolbol, S. K., Dannenberg, A. J., Mestre, J. R., Bilinski, R. T., Martucci, C., Newmark, H. L., Chadburn, A., and Bertagnolli, M. M. The sulfide metabolite of sulindac prevents tumors and restores enterocyte apoptosis in a murine model of familial adenomatous polyposis. Carcinogenesis (Lond.), 19: 87-91, 1998.
32. Wechter, C., Murray, E. J., Kantoci, D., Quiggle, D., Leipold, D., Gibon, K., and McCracken, J. Treatment studies of the APCmin/+ mouse with R-flubiprofen (R-FB), and sulindac sulfone (SS). Proc. Am. Assoc. Cancer Res., 39: 643, 1998.